Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
47 participants
INTERVENTIONAL
2010-05-31
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiple-Ascending Dose Study
NCT00892840
Single Dose Study of BMS-820836
NCT00964912
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
NCT01309945
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
NCT06280235
Prevention of Seasonal Affective Disorder
NCT00046449
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo or BMS-866949 (3 mg)
Panel 1: Healthy Male Subjects
Placebo
Oral Solution, Oral, 0 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 3 mg, Once Daily, 14 days
Placebo or BMS-866949 (10 mg)
Panel 2: Healthy Male Subjects
Placebo
Oral Solution, Oral, 0 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 10 mg, Once Daily, 14 days
Placebo or BMS-866949 (30 mg)
Panel 3: Healthy Male Subjects
Placebo
Oral Solution, Oral, 0 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 30 mg, Once Daily, 14 days
Placebo or BMS-866949 (45 mg)
Panel 4: Healthy Male Subjects
Placebo
Oral Solution, Oral, 0 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 45 mg, Once Daily, 14 days
Placebo or BMS-866949 (60 mg)
Panel 5: Healthy Male Subjects
Placebo
Oral Solution, Oral, 0 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 60 mg, Once Daily, 14 days
Placebo or BMS-866949 (90 mg)
Panel 6: Healthy Male Subjects
Placebo
Oral Solution, Oral, 0 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 90 mg, Once Daily, 14 days
Placebo or BMS-866949 (3 - 60 mg)
Panel 7: Females
Placebo
Oral Solution, Oral, 0 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Oral Solution, Oral, 0 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 3 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 10 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 30 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 45 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 60 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 90 mg, Once Daily, 14 days
BMS-866949
Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Panel 7: Females
* Ages 21 to 55, inclusive
* Body Mass Index (BMI) of 18 to 32 kg/m², inclusive
* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
Exclusion Criteria
* History or family history of psychiatric disorder
* Current treatment with prescription medication
* Exposure to any investigational drug or placebo within 12 weeks of study drug administration
21 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Investigator Inquiry form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-018461-38
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CN166-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.